$ZLAB

Zai Lab Ltd

Zai Lab is a global biopharmaceutical company focused on discovering, developing and commercializing medicines for conditions in oncology, immunology, neuroscience and infectious disease. It serves patients through commercial products and a pipeline of in-licensed and internally developed candidates. Zai Lab has a substantial presence in Greater China and the United States. The company has seven commercial programs with products launched in one or more Greater China territories. Its products include ZEJULA, VYVGART and VYVGART Hytrulo, NUZYRA, OPTUNE, QINLOCK, XACDURO and AUGTYRO. Zai Lab sells and promotes products through commercial teams covering sales, marketing, medical affairs, market access and distributor management; it also works with partners on commercialization and product development. Its research and development activities include internal discovery, clinical development and collaborations with biopharmaceutical companies and external research partners. Zai Lab is headquartered in Shanghai.

5
0
0
$33K
—
GAYNOR RICHARD
100%
See all $ZLAB insider activity →

Zai Lab Limited Adds 2 Drugs to China's NRDL

Zai Lab Limited announced that five of its commercial medicines, including two new drugs, KarXT and VYVGART Hytrulo, were added to China's National Reimbursement Drug List (NRDL) for 2026. The list will take effect on January 1, 2027, potentially impacting the company's sales and market access in China.

ZLAB sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 5 news stories mentioning ZLAB (Zai Lab Ltd). Coverage has skewed bullish: 5 bullish, 0 neutral, and 0 bearish.

Recent ZLAB coverage spans financial news, technology and regulation.

In the last 30 days, ZLAB insiders filed 1 SEC Form 4 transaction — 1 purchase ($33K) and no sales. The most active reporter was GAYNOR RICHARD with 1 filing. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.

What's driving ZLAB

AlphAI scores every news story that mentions ZLAB with an AI model for sentiment and relevance, and aggregates insider trades from Zai Lab Ltd's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $ZLAB

Score

Zai Lab Limited Adds 2 Drugs to China's NRDL

Zai Lab Limited announced that five of its commercial medicines, including two new drugs, KarXT and VYVGART Hytrulo, were added to China's National Reimbursement Drug List (NRDL) for 2026. The list will take effect on January 1, 2027, potentially impacting the company's sales and market access in China.

$ZLABHighAI 8/10

Zai Lab Announces Third Quarter 2026 Financial Results and Recent Corporate Updates

Zai Lab reported Q3 2026 revenue of $116.1M, up 2% sequentially. The company anticipates key milestones in 2027, including Phase 3 studies for zocilurtatug pelitecan (zoci) in SCLC and potential FDA submissions. ZL-1503, an IL-13/IL-31Rα bispecific antibody, is advancing toward clinical milestones. Zai Lab raised $250M in a private placement to fund pipeline development.

Zai Lab Limited: Zai Lab's Zocilurtatug Pelitecan (Zoci, Formerly ZL-1310) Demonstrates High Response Rates, Encouraging Durability and Well-Tolerated Safety Profile in First-Line Extensive-Stage Small Cell Lung Cancer

Zai Lab's (ZLAB) drug zocilurtatug pelitecan (zoci) showed 81.8% response rate and 81.9% 6-month progression-free survival in a Phase 1b trial for extensive-stage small cell lung cancer. The combination with atezolizumab was well-tolerated. A Phase 3 trial is planned for 2026. Zai Lab will discuss the data in an investor call.

First human data on an experimental eczema treatment will be presented in November. It comes from healthy volunteers.

Zai Lab (ZLAB) will present Phase 1/1b trial data for ZL-1503, an experimental eczema treatment, at ACAAI 2026. The data, from healthy volunteers, includes pharmacokinetic and pharmacodynamic results. ZL-1503 targets IL-13 and IL-31, aiming to provide rapid itch relief and reduce inflammation. An investor conference call is scheduled for November 13, 2026.

Cantor Fitzgerald reiterates Zai Lab stock rating on ADC potential

Cantor Fitzgerald reiterated an Overweight rating and $37 price target for Zai Lab (ZLAB), citing potential for its DLL3 ADC, zocilurtatug, in small cell lung cancer. The stock is up 45% year-to-date. Zai Lab's Q2 earnings beat expectations with $106.3M revenue and adjusted EPS of -$0.05. Analysts maintain a Strong Buy consensus with price targets ranging from $24.25 to $50.

Zai Lab Limited: Zai Lab to Present First Global Data from Clinical Trial Evaluating Zocilurtatug Pelitecan (Zoci) As First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

Zai Lab (ZLAB) will present global clinical trial data on zocilurtatug pelitecan (zoci) for first-line extensive-stage small cell lung cancer (ES-SCLC) at ESMO Congress 2026. The trial evaluates zoci in combination with atezolizumab with or without carboplatin. An investor call is scheduled for October 23, 2026, to discuss the data and future plans. Zai Lab highlights zoci's potential as a backbone ADC in ES-SCLC treatment.

Related tickers